SEER, Inc. launches an IPO.

An IPO of Seer, Inc. (SEER) will take place on December 3, 2020. Seer is a biomedical company that seeks to commercialise products for proteome research. The company’s first product - Proteograph Product Suite (Proteograph), will use its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome. Proteograph Product Suite is an integrated solution of consumables, an automation instrument and software. Proteograph provides a simple workflow. With the help of this product proteomic profiling and analysis of the thousands of samples required to characterise the complex and dynamic proteome’s nature can be performed at almost any laboratory.
Listed underwriters of the IPO are J.P. Morgan, Morgan Stanley, BofA Securities and Cowen.